| Dr Monique Mohammed-weeks, OD, MS | |
|
4487 3rd Ave, Bronx, NY 10457-1526 | |
| (718) 960-9000 | |
| Not Available |
| Full Name | Dr Monique Mohammed-weeks |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 4487 3rd Ave, Bronx, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063002541 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 009306 (New York) | Primary |
| Provider Name | Sbh Physicians Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1740595917 PECOS PAC ID: 3072798941 Enrollment ID: O20110420000217 |
News Archive
With many types of cancers, early detection offers the best hope for survival. However, research into new early-detection screenings, as well as possible interventional radiology and surgical treatments, has been hindered by the lack of a large animal model that would accurately reflect the types of cancers seen in human cells.
Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.
Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.
Research teams dedicated to improving the health of all New Zealanders now have a new home at The University of Auckland's Population Health Complex.
Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Monique Mohammed-weeks, OD, MS 4487 3rd Ave, Dept Of Ophthalmology, Bronx, NY 10457-1526 Ph: (718) 960-9000 | Dr Monique Mohammed-weeks, OD, MS 4487 3rd Ave, Bronx, NY 10457-1526 Ph: (718) 960-9000 |
News Archive
With many types of cancers, early detection offers the best hope for survival. However, research into new early-detection screenings, as well as possible interventional radiology and surgical treatments, has been hindered by the lack of a large animal model that would accurately reflect the types of cancers seen in human cells.
Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.
Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.
Research teams dedicated to improving the health of all New Zealanders now have a new home at The University of Auckland's Population Health Complex.
Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 4 days ago
Ms. Deborah Esposito, Optometrist Medicare: Not Enrolled in Medicare Practice Location: 26 Holly Pl, Bronx, NY 10465 Phone: 917-217-6935 | |
Clear View Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 707 Burke Ave, Bronx, NY 10467 Phone: 718-547-1600 | |
Vision Quest Bronx Optometrist Medicare: Medicare Enrolled Practice Location: 905 White Plains Rd, Bronx, NY 10473 Phone: 718-239-9389 | |
Creston Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2169 White Plains Rd, Bronx, NY 10462 Phone: 718-409-2200 | |
Pro Optics Corp Optometrist Medicare: Medicare Enrolled Practice Location: 2483 Grand Concourse, Bronx, NY 10468 Phone: 718-933-0187 | |
Fordham Vision Center Ny Llc Optometrist Medicare: Medicare Enrolled Practice Location: 1 E Fordham Rd, Bronx, NY 10468 Phone: 718-733-6700 Fax: 718-733-2756 | |
Veronica Moore-stoll, OD Optometrist Medicare: Medicare Enrolled Practice Location: 3130 Grand Concourse Ste B6, Bronx, NY 10458 Phone: 718-741-3200 |